| 80.39 -0.13 (-0.16%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 100.47  |
1-year : | 117.35 |
| Resists | First : | 86.01 |
Second : | 100.47 |
| Pivot price | 81.02 |
|||
| Supports | First : | 78.9 |
Second : | 74.5 |
| MAs | MA(5) : | 80.51 |
MA(20) : | 80.97 |
| MA(100) : | 87.54 |
MA(250) : | 75.94 |
|
| MACD | MACD : | -1.3 |
Signal : | -1.7 |
| %K %D | K(14,3) : | 36.8 |
D(3) : | 40.4 |
| RSI | RSI(14): 45.4 |
|||
| 52-week | High : | 101.4 | Low : | 51.79 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ GMED ] has closed above bottom band by 42.5%. Bollinger Bands are 25.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 80.96 - 81.62 | 81.62 - 82.06 |
| Low: | 78.43 - 79.16 | 79.16 - 79.66 |
| Close: | 79.43 - 80.57 | 80.57 - 81.33 |
Globus Medical, Inc. is a global medical technology company dedicated to inventing, developing, and marketing a diverse range of healthcare solutions. Their primary focus is on addressing musculoskeletal disorders for patients worldwide. Their extensive portfolio includes a variety of spinal products. These encompass traditional fusion implants like pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices, all designed to treat conditions such as degenerative diseases, deformities, tumors, and trauma. Furthermore, they offer advanced motion preservation technologies, including dynamic stabilization, total disc replacement, and interspinous distraction devices. The company also provides interventional pain management options for vertebral compression fractures, alongside a selection of regenerative biologic products such as allografts and synthetic alternatives. Beyond spinal care, Globus Medical manufactures solutions for orthopedic trauma, featuring products like fracture plates, compression screws, intramedullary nails, and external fixation systems. They also specialize in hip and knee joint reconstruction, offering modular hip stems, acetabular cups, and various knee arthroplasty implants, including posterior stabilizing and cruciate retaining designs. Additionally, the company engages in the distribution of human cell, tissue, and other cellular and tissue-based products. Established in 2003, Globus Medical, Inc. maintains its corporate headquarters in Audubon, Pennsylvania.
Fri, 12 Jun 2026
Madison Small Cap Fund Sold Globus Medical (GMED) as Valuation Exceeded - Yahoo Finance
Thu, 11 Jun 2026
Is It Time To Reassess Globus Medical (GMED) After Its Recent Share Price Recovery? - Yahoo Finance
Thu, 11 Jun 2026
Globus Medical (NYSE:GMED) Shines in Navellier's Little Book Growth Stock Screen - ChartMill
Tue, 09 Jun 2026
Globus Medical Inc (GMED) Stock Up 5.4% and Still Undervalued -- GF Score: 97/100 - GuruFocus
Tue, 09 Jun 2026
Here is Why Globus Medical (GMED) is One of the Most Profitable Growth Stocks to Buy - Insider Monkey
Tue, 09 Jun 2026
Globus Medical (NYSE: GMED) director exercises options, sells 25,000 shares - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 113 (M) |
| Shares Float | 112 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 101.5 (%) |
| Shares Short | 3,410 (K) |
| Shares Short P.Month | 3,310 (K) |
| EPS | 4.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 34.88 |
| Profit Margin | 18.9 % |
| Operating Margin | 21.3 % |
| Return on Assets (ttm) | 8.1 % |
| Return on Equity (ttm) | 13.3 % |
| Qtrly Rev. Growth | 27 % |
| Gross Profit (p.s.) | 18.7 |
| Sales Per Share | 27.35 |
| EBITDA (p.s.) | 8.34 |
| Qtrly Earnings Growth | 66.6 % |
| Operating Cash Flow | 779 (M) |
| Levered Free Cash Flow | 341 (M) |
| PE Ratio | 18.78 |
| PEG Ratio | 1.4 |
| Price to Book value | 2.3 |
| Price to Sales | 2.93 |
| Price to Cash Flow | 11.7 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|